Hypercholesterolemia - Pipeline Review, H2 2016

Date: November 23, 2016
Pages: 214
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H807BC988B3EN
Leaflet:

Download PDF Leaflet

Hypercholesterolemia - Pipeline Review, H2 2016
Hypercholesterolemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia – Pipeline Review, H2 2016, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 13, 5, 1, 17, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.Hypercholesterolemia.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
Pipeline Products for Hypercholesterolemia - Overview
Pipeline Products for Hypercholesterolemia - Comparative Analysis
Hypercholesterolemia - Therapeutics under Development by Companies
Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes
Hypercholesterolemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hypercholesterolemia - Products under Development by Companies
Hypercholesterolemia - Products under Investigation by Universities/Institutes
Hypercholesterolemia - Companies Involved in Therapeutics Development
3SBIO INC
AFFiRiS AG
Akcea Therapeutics Inc
Alvogen Korea Co Ltd
ARMO Biosciences Inc
AstraZeneca Plc
BioLingus AG
Catabasis Pharmaceuticals Inc
Chong Kun Dang Pharmaceutical Corp
CymaBay Therapeutics Inc
Daewon Pharm Co Ltd
Dicerna Pharmaceuticals Inc
Dybly AG
Esperion Therapeutics Inc
Gemphire Therapeutics Inc
Golden Biotechnology Corp
Hanmi Pharmaceuticals Co Ltd
Immune Response BioPharma Inc
Johnson & Johnson
Kadmon Corp LLC
Kyorin Pharmaceutical Co Ltd
Leading BioSciences Inc
LipimetiX Development Inc
Lotus Pharmaceutical Co Ltd
Merck & Co Inc
Pfizer Inc
Planet Biotechnology Inc
Progenra Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Solvotrin Therapeutics Ltd
The Medicines Company
Thetis Pharmaceuticals LLC
Viking Therapeutics Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Hypercholesterolemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aspirin + lisinopril + lovastatin) - Drug Profile
(atorvastatin calcium + ezetimibe) - Drug Profile
(atorvastatin calcium + ezetimibe) - Drug Profile
(atorvastatin calcium + TP-452) - Drug Profile
(bempedoic acid + ezetimibe) - Drug Profile
(candesartan cilexetil + rosuvastatin calcium) - Drug Profile
(ezetimibe + rosuvastatin calcium) - Drug Profile
AEM-28 - Drug Profile
AEM-2802 - Drug Profile
AEM-2814 - Drug Profile
alirocumab - Drug Profile
AM-0010 - Drug Profile
anacetrapib - Drug Profile
Antibodies for Metabolic Disorders - Drug Profile
Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile
antroquinonol - Drug Profile
ATH-04 - Drug Profile
ATH-06 - Drug Profile
bempedoic acid - Drug Profile
BSN-272 - Drug Profile
CAT-2000 Series - Drug Profile
CAT-2003 - Drug Profile
colestilan chloride - Drug Profile
D-4F - Drug Profile
DCRPCSK-9 - Drug Profile
Drugs for Hypercholesterolemia - Drug Profile
Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile
DW-0929 - Drug Profile
DW-3102 - Drug Profile
DYB-186 - Drug Profile
EP-80317 - Drug Profile
evinacumab - Drug Profile
gemcabene calcium - Drug Profile
Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
HCP-1305 - Drug Profile
HGP-0816 - Drug Profile
HS-25 - Drug Profile
inclisiran - Drug Profile
IONIS-ANGPTL3LRx - Drug Profile
IR-1002 - Drug Profile
KD-026 - Drug Profile
MBX-8025 - Drug Profile
MGL-3196 - Drug Profile
MGL-3745 - Drug Profile
MN-002 - Drug Profile
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
PF-06446846 - Drug Profile
Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
RGX-501 - Drug Profile
rosuvastatin calcium - Drug Profile
Small Molecule for Hypercholesterolemia - Drug Profile
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Small Molecules to Inhibit IDOL for Hypercholesterolemia - Drug Profile
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
ST-0702 - Drug Profile
SX-PCK9 - Drug Profile
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile
VK-2809 - Drug Profile
volanesorsen sodium - Drug Profile
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 209

LIST OF TABLES

Number of Products under Development for Hypercholesterolemia, H2 2016
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Hypercholesterolemia - Pipeline by 3SBio Inc, H2 2016
Hypercholesterolemia - Pipeline by AFFiRiS AG, H2 2016
Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H2 2016
Hypercholesterolemia - Pipeline by Alvogen Korea Co Ltd, H2 2016
Hypercholesterolemia - Pipeline by ARMO Biosciences Inc, H2 2016
Hypercholesterolemia - Pipeline by AstraZeneca Plc, H2 2016
Hypercholesterolemia - Pipeline by BioLingus AG, H2 2016
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016
Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H2 2016
Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H2 2016
Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
Hypercholesterolemia - Pipeline by Dybly AG, H2 2016
Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H2 2016
Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H2 2016
Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H2 2016
Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H2 2016
Hypercholesterolemia - Pipeline by Johnson & Johnson, H2 2016
Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H2 2016
Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H2 2016
Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H2 2016
Hypercholesterolemia - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016
Hypercholesterolemia - Pipeline by Merck & Co Inc, H2 2016
Hypercholesterolemia - Pipeline by Pfizer Inc, H2 2016
Hypercholesterolemia - Pipeline by Planet Biotechnology Inc, H2 2016
Hypercholesterolemia - Pipeline by Progenra Inc, H2 2016
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Hypercholesterolemia - Pipeline by RegenxBio Inc, H2 2016
Hypercholesterolemia - Pipeline by Serometrix LLC, H2 2016
Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016
Hypercholesterolemia - Pipeline by Solvotrin Therapeutics Ltd, H2 2016
Hypercholesterolemia - Pipeline by The Medicines Company, H2 2016
Hypercholesterolemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2016
Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H2 2016
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hypercholesterolemia - Dormant Projects, H2 2016
Hypercholesterolemia - Dormant Projects (Contd..1), H2 2016
Hypercholesterolemia - Dormant Projects (Contd..2), H2 2016
Hypercholesterolemia - Dormant Projects (Contd..3), H2 2016
Hypercholesterolemia - Dormant Projects (Contd..4), H2 2016
Hypercholesterolemia - Dormant Projects (Contd..5), H2 2016
Hypercholesterolemia - Dormant Projects (Contd..6), H2 2016
Hypercholesterolemia - Discontinued Products, H2 2016
Hypercholesterolemia - Discontinued Products (Contd..1), H2 2016 195

LIST OF FIGURES

Number of Products under Development for Hypercholesterolemia, H2 2016
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Hypercholesterolemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: